Tao Fu joined Portola Pharmaceuticals in June 2015 with 18 years of experience in business development, commercial strategy and management consulting in the biopharmaceutical industry. Prior to joining Portola, he was vice president and head of mergers and acquisitions and alliance management at Bristol-Myers Squibb where he was responsible for the company’s corporate development, alliance management and venture activities. Previously, he was vice president, business development at Janssen (Johnson & Johnson) where he was responsible for over 20 business development transactions, including the execution of the . license and collaboration agreement with Bayer for Xarelto ® (rivaroxaban). Earlier in his career, he held positions at Scios Inc. (a Johnson & Johnson company), McKinsey & Company, and Becton Dickinson.